Advertisement

What Medications Commonly Given in the Acute Care Setting Are Safe in Liver Failure and Cirrhosis? In What Doses?

  • Amber RuestEmail author
Chapter

Abstract

No evidence-based guidelines exist for the use of medication in patients with liver cirrhosis; however based on drug pharmacokinetics, many medications require dosage adjustment. Acetaminophen can be used safely at low doses (≤2–3 g daily) for short durations and should be considered first-line treatment for pain as opioids can precipitate hepatic encephalopathy. Nonsteroidal anti-inflammatory drugs should be avoided as they predispose to renal failure and gastrointestinal bleeding in this population. Opioids and sedative medications should be avoided, and, if necessary, they should be given with reduced dosage or frequency. Cirrhotic patients may take prophylactic medications, and acute care providers should understand the potential for associated adverse effects.

Keywords

Medications Acetaminophen Ibuprofen Hepatotoxic Dosing Cirrhosis 

References

  1. 1.
    Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ther. 2013;37:1132.CrossRefGoogle Scholar
  2. 2.
    Verbeeck RK. Pharmacokinetics and dosage adjustments in patient with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–61.CrossRefGoogle Scholar
  3. 3.
    Bosilkovska M, Walder B, Besson M, et al. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012;72:1645–69.CrossRefGoogle Scholar
  4. 4.
    Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37:17–40.CrossRefGoogle Scholar
  5. 5.
    Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–24.CrossRefGoogle Scholar
  6. 6.
    Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anesth Intensive Care. 2005;33:311–22.Google Scholar
  7. 7.
    Lee YC, Chang CH, Lin JW, et al. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012;32:859–66.CrossRefGoogle Scholar
  8. 8.
    Lebrec D, Poynard T, HIllon P, Benhamou J-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patents with cirrhosis-a controlled study. N Engl J Med. 1981;305:1371–4.CrossRefGoogle Scholar
  9. 9.
    Pascal J-P, Cales P, Multicenter Study Group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1987;317:856–61.CrossRefGoogle Scholar
  10. 10.
    Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967–9.CrossRefGoogle Scholar
  11. 11.
    Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643–53.CrossRefGoogle Scholar
  12. 12.
    Ge PS, Runyon BA. A review article: treatment of patients with cirrhosis. N Engl J Med. 2016;375:767–77.CrossRefGoogle Scholar
  13. 13.
    Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–7.CrossRefGoogle Scholar
  14. 14.
    Saab S, Hernandez JC, Chi AC, Tong MJ. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol. 2009;104:993–1001.CrossRefGoogle Scholar
  15. 15.
    O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–9. e1.CrossRefGoogle Scholar
  16. 16.
    Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(Suppl 6):vi1–vi12.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680–5.CrossRefGoogle Scholar
  18. 18.
    Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2012;27(8):1329–35.CrossRefGoogle Scholar
  19. 19.
    Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.CrossRefGoogle Scholar
  20. 20.
    Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther. 2012;3(4):62–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Emergency MedicineWellspan York HospitalYorkUSA

Personalised recommendations